Tuberculosis remains one of the most consequential infectious disease challenges of our era, and a sweeping new analysis reveals precisely where the world stands — and how far it has to go — before looming funding cuts erode decades of hard-won progress. For anyone tracking longevity and infectious disease burden, this dataset offers the most granular picture yet of how TB, HIV co-infection, and drug resistance intersect across populations.
Drawing on the Global Burden of Disease Study 2023, researchers analyzed TB mortality, incidence, prevalence, and disability-adjusted life-years (DALYs) across 204 countries and territories from 1990 to 2023. The analysis stratified outcomes by HIV status and drug-resistance profile — including multidrug-resistant TB (MDR-TB) — using a population attributable fraction framework. Modelling incorporated vital registration data, surveillance records, verbal autopsies, and minimally invasive tissue sampling, processed through the DisMod-MR 2.1 platform. Risk factor contributions from alcohol use, smoking, and elevated fasting plasma glucose were also quantified using comparative risk assessment methods.
The significance of this analysis extends well beyond epidemiological bookkeeping. MDR-TB represents one of the most pressing antimicrobial resistance threats globally, with treatment success rates substantially lower than drug-susceptible strains and treatment costs orders of magnitude higher. The WHO End TB Strategy targets — a 95% reduction in deaths and 90% reduction in incidence by 2035 from a 2015 baseline — were already considered ambitious; this study provides a 2023 progress checkpoint at a moment when global health financing is contracting. Historically, TB burden has been tightly coupled to HIV prevalence, poverty, and healthcare access, and GBD analyses have consistently revealed that aggregate global improvements mask severe regional heterogeneity, particularly across sub-Saharan Africa and South Asia. This is an observatory-scale, systematic analysis rather than a causal trial, so it cannot resolve questions about intervention efficacy. Its primary value is as a baseline and accountability tool — one whose timing, given current funding pressures, makes it more politically and practically urgent than a routine epidemiological update.